Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Aleksandr Ianevski
  • Jenni Lahtela
  • Komal K. Javarappa
  • Philipp Sergeev
  • Bishwa R. Ghimire
  • Prson Gautam
  • Markus Vähä-Koskela
  • Laura Turunen
  • Nora Linnavirta
  • Kuusanmäki, Heikki Aleksi
  • Mika Kontro
  • Kimmo Porkka
  • Caroline A. Heckman
  • Pirkko Mattila
  • Wennerberg, Krister
  • Anil K. Giri
  • Tero Aittokallio

The extensive drug resistance requires rational approaches to design personalized combinatorial treatments that exploit patient-specific therapeutic vulnerabilities to selectively target disease-driving cell subpopulations. To solve the combinatorial explosion challenge, we implemented an effective machine learning approach that prioritizes patient-customized drug combinations with a desired synergy-efficacy-toxicity balance by combining single-cell RNA sequencing with ex vivo single-agent testing in scarce patient-derived primary cells. When applied to two diagnostic and two refractory acute myeloid leukemia (AML) patient cases, each with a different genetic background, we accurately predicted patient-specific combinations that not only resulted in synergistic cancer cell co-inhibition but also were capable of targeting specific AML cell subpopulations that emerge in differing stages of disease pathogenesis or treatment regimens. Our functional precision oncology approach provides an unbiased means for systematic identification of personalized combinatorial regimens that selectively co-inhibit leukemic cells while avoiding inhibition of nonmalignant cells, thereby increasing their likelihood for clinical translation.

TidsskriftScience Advances
Udgave nummer8
StatusUdgivet - 2021

Antal downloads er baseret på statistik fra Google Scholar og

Ingen data tilgængelig

ID: 257744067